The effect of gastrografin and glucagon on CT scanning of the pancreas: a blind clinical trial.
The effect of Gastrografin and glucagon on pancreatic CT scanning was studied in a blind clinical trial. Twenty-five patients had a pancreatic CT scan performed on an 18-second scanner and a repeat pancreatic CT scan following administration of Gastrografin and glucagon. The results were statistically significant: decreased streak artifacts; improved pancreatic head, body and tail delineation; and improved overall pancreatic visualization. Gastrografin-glucagon administration is recommended prior to pancreatic CT scanning if the scanning cycle is 18 seconds or longer.
D003973:Diatrizoate; D005934:Glucagon; D006801:Humans; D010182:Pancreatic Diseases / Q000000981:diagnostic imaging*; D014057:Tomography, X-Ray Computed
D003973:Diatrizoate; D005934:Glucagon